Research programme: Discoidin Domain Receptor Inhibitors - Redx Pharma
Alternative Names: Research programme: DDR Inhibitors - Redx Pharma; RXC-009Latest Information Update: 26 Apr 2022
At a glance
- Originator Redx Pharma
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Discoidin domain receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
Most Recent Events
- 19 Apr 2022 Preclinical development in Fibrosis in United Kingdom (unspecified route) (Redx pharma pipeline, April 2022)
- 19 Apr 2022 Redx pharma plans IND submission in 2025 (Redx pharma pipeline, April 2022)